Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Circulating tumor cells (dependent on 1⁰ genomic events, high-risk 2⁰ events (amp 1q, del 1p, del 13q, biallelic TP53 mutations, increased APOBEC)) are a compound biomarker for BM high-risk genomic alterations/tumor load.”
Title: Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load
Authors: Cathelijne Fokkema, Luca Bertamini, Madelon M.E. de Jong, Sabrin Tahri, Davine Hofste op Bruinink, Zoltan Kellermayer, Natalie Papazian, Chelsea den Hollander, Michael Vermeulen, Elodie C.G. Stoetman, Gregory van Beek, Remco Hoogenboezem, Vincent H.J. van der Velden, Cyrille Hulin, Aurore Perrot, Philippe Moreau, Melissa Rowe, Diego Vieyra, Robin Carson, Mark van Duin, Mathijs Arnoud Sanders, Annemiek Broijl, Peter Sonneveld, Tom Cupedo
You can read the Full Article in Blood.
You can find more posts featuring Robert Orlowski on OncoDaily.
